




Division Head,
Hematology,
Oncology,
Neuro-Oncology
and Stem Cell
Transplant

LEADERSHIP PROFILE

JULY 2026

WittKieffer

*Prepared by Kerry Quealy, Jeff Schroetlin,
and Fayth Hoecker*





CONTENTS

- 01** The Opportunity
- 03** Position Summary
- 05** Candidate Qualifications
- 06** Organization Overview
- 16** The Community
- 17** Procedure for Candidacy



THE OPPORTUNITY

Ann & Robert H. Lurie Children's Hospital of Chicago (Lurie Children's) seeks an accomplished and transformational leader to serve as Division Head of Hematology, Oncology, Neuro Oncology, and Stem Cell Transplant. The successful candidate will have the opportunity to substantially build upon a complex, high impact pediatric cancer and blood disorders program and to partner to propel it as among the nation's best.

Ann & Robert H. Lurie Children's Hospital of Chicago is one of the premier children's hospitals in the country and the only freestanding hospital in Illinois exclusively for children. Lurie Children's medical staff includes more than 1,800 physicians and allied health professionals who offer expertise in 70 pediatric specialty areas. With an inpatient capacity of 360 beds, more than 230,000 children from around the world receive the highest quality medical care each year at Lurie Children's. Lurie Children's has 14 outpatient centers and five primary care locations throughout Chicago and its suburbs. Lurie Children's is on the medical campus of Northwestern University in Chicago and is connected via an enclosed pedestrian bridges to Northwestern Memorial Hospital and Northwestern Medicine Prentice Women's Hospital. Lurie Children's is the pediatric training and teaching hospital of Northwestern University Feinberg School of Medicine and one of a few children's hospitals in the country to have its own research center devoted to pediatric diseases, Stanley Manne Children's Research Institute.

The Division is staffed by 35 distinguished faculty members and 42 advanced practice providers who offer exceptional clinical care, innovative scientific research and comprehensive educational programs for students and trainees. The Division actively participates in national research and clinical consortiums while holding a well-established portfolio of extramural funding. It also works in close cooperation with Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Lurie Children's CCBD treats more children with cancer and blood disorders than any other hospital in the state.

The Division Head will elevate research and clinical programs while sustaining strategic growth by leveraging a robust infrastructure and a supportive world-class comprehensive cancer center. This leader will articulate and implement a leading research program for the Division, exploring disease mechanisms from the molecular level to developing transformative therapies in the clinical setting. Serving as Service Line Chief, the Division Head will oversee the delivery of a full spectrum of advanced, multidisciplinary clinical care, access to cutting-edge treatments, outstanding patient outcomes, and comprehensive support services for patients and their families while advancing innovative clinical and translational research. Building on a strong tradition of physician and physician-scientist development through an ACGME-accredited fellowship program, the Division Head will continue to strengthen medical education and mentorship, cultivating the next generation of leaders in the field. This physician leader will embody and advance the Division and Lurie Children's commitment to fostering an inclusive environment and serving the underrepresented with world-class care.

The ideal candidate will be a leader and a builder with a strong commitment to enhancing patient and family-centered care and outcomes. They will exhibit a collaborative leadership style and possess extensive experience in navigating complex academic environments. A distinguished record of advancing scientific programs and securing extramural funding in pediatric hematology/ oncology is crucial. The candidate should have a proven track record of fostering accountability, effectively leading and managing teams and recruiting and developing faculty and staff. The ability to collaborate with multiple stakeholders and partners is critical to the success of the Division. A medical degree (MD/DO) or MD/PhD, board certification in pediatric hematology, oncology and stem cell transplant and eligibility for an Associate Professor or Professor-level appointment at Northwestern University are required.





POSITION SUMMARY

The Division Head will provide visionary leadership and advance excellence in pediatric hematology, oncology, and neuro-oncology and stem cell transplant through the integrated missions of research, clinical care, and education. This leader will drive innovative growth of research programs that promote collaboration and innovation across the organization. The Division Head will contribute to leading and developing the evolving Cancer Service Line at Lurie Children's and has overall accountability for clinical operations, programmatic development, and performance, ensuring delivery of high-quality, patient-centered care. They will lead a strong teaching program mentoring trainees and junior faculty while cultivating the next generation of physician-scientists. The Division Head will promote a culture of continuous learning and ensure collaboration, accountability, and innovation across all mission areas. They will foster an inclusive and respectful environment that supports professional development, and enhances team engagement and well-being.

REPORTING RELATIONSHIPS

The Division Head will report to the Chair, Department of Pediatrics. Direct reports to the Division Head will include Section Heads of Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplantation, Fellowship program directors, Core Directors of QI/Safety, Experimental Therapeutics, and Education, Research Leadership including Precision Oncology, COG Site PI, PEP-CTN Site PI, and the Director of Basic Science/Translational Research, and all faculty members.

The Division Head will partner extensively with the Service Line Executive Director, Division Administrator, APP Director, Nursing Director, and Research Associate Director in management of all staff within the CCBD.

This leader will have key relationships with Lurie Children's Hospital leadership, the President of the Lurie Children's Medical Group, leaders in the Stanley Manne Children's Research Institute, and other Division Heads within the Department.

Additional key relationships include the leaders in the Robert H. Lurie Comprehensive Cancer Center and across Northwestern Medicine.

OPPORTUNITIES AND EXPECTATIONS OF LEADERSHIP

Develop and Execute a Transformational Vision

Lurie Children's has a strong brand and a meaningful leadership position within a dynamic and competitive market. The Division Head will inherit a Division with many foundational strengths including talented faculty, institutional commitment to growth, and respected and committed leadership. The next leader will define and advance a vision that positions the program as a destination for highly specialized pediatric cancer care and research. This includes establishing clear growth priorities that build signature clinical and research programs, expand regional and national reach, and leverage institutional and philanthropic investment to drive innovation.

Enhance Clinical Delivery and Access

The Cancer Service Line is evolving, and Lurie Children's is well-positioned to further enhance its clinical delivery model to meet expectations for access and experience. The next Division Head will lead efforts to optimize care models, improve patient flow, and expand access, ensuring that the Division fully leverages its clinical strengths. This includes advancing multidisciplinary care, refining care pathways, and maximizing the contributions of advanced practice providers in delivering care at the top of their license. By thoughtfully evolving how care is delivered, the Division can strengthen its regional presence and better serve a broader and increasingly complex patient population.

Elevate Research and Academic Performance

With strong institutional commitment and emerging infrastructure, the Division is poised to significantly expand its research enterprise. The Division Head will play a central role in shaping a more coordinated and high-impact research strategy, connecting basic, translational, and clinical efforts. There is a compelling opportunity to grow clinical trials activity, enhance translational science, and further increase external funding. Strengthening partnerships with the Lurie Cancer Center and Northwestern's adult oncology programs will be critical to achieving this vision, positioning the Division as a key contributor to broader cancer initiatives and elevating its national scientific profile.

Recruit and Develop High-Impact Faculty

The Division has a strong and committed faculty, providing a solid platform for continued growth. The next leader will build on this by recruiting additional high-impact faculty and further strengthening leadership depth across programs. Targeted recruitment of senior physician-scientists and program builders will enhance both clinical and research capabilities. Equally important will be advancing a structured approach to faculty development.

Leverage an Aligned, High-Performance Culture

The Division benefits from a culture of collaboration, transparency, and shared purpose. The Division Head will foster strong communication, align teams around a common vision, and reinforce a culture where clinical excellence, research engagement, and teamwork are all highly valued. By clearly articulating priorities and engaging faculty and staff in the Division's evolution, the leader will help ensure broad alignment and continued engagement. This work will build on an already mission-driven community and support an environment where individuals and programs can thrive collectively.

Strengthen Operational and Financial Performance

The next leader will work closely with service line and institutional partners to advance data-driven decision-making, improve resource alignment, and optimize performance across clinical and research operations. This includes strengthening visibility into metrics such as productivity, access, and program performance, as well as ensuring that resources are effectively aligned with strategic priorities. By further developing these capabilities, the Division can scale efficiently and support both mission-driven and financially sustainable growth. The opening of a new hospital in Downers Grove, IL is a significant strategic growth opportunity that will require thoughtful planning regarding oncology program expansion and regional care delivery.



CANDIDATE QUALIFICATIONS

EDUCATION/CERTIFICATION

- MD or equivalent degree, or MD/PhD from an accredited institution
- Board-certified in Pediatrics with fellowship training in Hematology, Oncology, or Stem Cell Transplantation
- Eligible for licensure as a physician in the state of Illinois
- Candidates must qualify for appointment at the Associate Professor or Professor level

KNOWLEDGE, WORK EXPERIENCE, AND COMPETENCIES

- A national reputation in pediatric hematology, oncology, neuro-oncology, and/or stem cell transplantation with a proven track record of securing external funding, conducting scholarly research activity, providing education, and delivering exceptional clinical care.
- Ability to build relationships, lead philanthropic efforts, and serve as a figurehead of the Division in the community and on the national stage.
- An exceptional recruiter with superior people management and leadership abilities, the capacity to serve as a mentor and facilitate the development of leadership and research skills among faculty within the Division.
- An astute understanding of academic clinical practice and a deep commitment to clinical excellence based on patient-centered and equitable model of care.
- Distinguished research leadership with demonstrated success securing research funding and/or leading major clinical research initiatives; deep understanding of clinical trial infrastructure; commitment to supporting and recruiting physician-scientists.
- Proven excellence in teaching and demonstrated history of fostering professional growth and development for faculty, staff, and learners.
- Possess exceptional interpersonal skills; has an open, transparent and objective manner and the ability to relate effectively with a wide variety of constituents and stakeholders; is tactful, politically savvy, and diplomatic while also able to demonstrate conviction in leading changes and meeting goals.
- A proven record as a visionary and strategic thinker, an accomplished negotiator and an effective organizational leader.
- Possesses a deep comprehension of the interrelated missions of education, research, patient care, and community involvement that characterizes academic medical practice and the importance of balancing these objectives.
- Establishes trust both within and outside the Division by seeking to understand differing perspectives, acting with transparency, and upholding commitments.
- Demonstrated skills and willingness to become a leader within a departmental and institutional ecosystem that includes connected missions stretching far outside the Division.



ORGANIZATION OVERVIEW

CENTER FOR CANCER AND BLOOD DISORDERS (CCBD) AT LURIE CHILDREN'S HOSPITAL

[The Center for Cancer and Blood Disorders \(CCBD\) at Lurie Children's Hospital](#) is nationally ranked by *U.S. News & World Report* and comprises a total of 35 physician/physician scientist faculty and two PhD research faculty as well as 42 ambulatory and inpatient advanced practice providers across sections of Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplantation.

The CCBD serves patients and families across several settings, including 1) 48 dedicated, private inpatient beds with positive pressure and HEPA filtration to accommodate all immunocompromised children with cancer and patients who undergo stem cell transplantation, cellular therapies and gene-based therapies; 2) a 26-bed Ambulatory Infusion Center, including nine beds for stem cell transplant and other patients undergoing therapeutic apheresis, extracorporeal photopheresis and stem cell collection; 3) Outpatient center with 18 private clinic rooms, three triage rooms and adjacent phlebotomy and CCBD-dedicated pharmacy facilities; and 4) Radiation therapy facilities at the adjacent and physically connected Northwestern Memorial Hospital.

Lurie also has rich network of ambulatory satellite outpatient centers throughout city of Chicago and greater Chicagoland area with CCBD presence at five locations, including our newest outreach site in Schaumburg, IL, which is also the home of a second 10-bed infusion center. Besides outreach, we have a comprehensive partnership with Central DuPage Hospital (CDH), located 37 miles west from Lurie, where two additional pediatric hematology/oncology physicians provide care and are considered faculty at NUFSON. CDH is also where a proton therapy center is located. The Division also has a longstanding partnership with colleagues in the Division of Hematology & Oncology (Department of Medicine) and the Robert H. Lurie Comprehensive Cancer Center, which is part of Northwestern Medicine and located on the same Streeterville campus as Lurie.

DIVISION OF PEDIATRIC HEMATOLOGY, ONCOLOGY, NEURO-ONCOLOGY AND STEM CELL TRANSPLANT

The CCBD and the Division of Hematology, Oncology, Neuro-Oncology & Stem Cell Transplant together represent a nationally ranked program in Chicago and the Chicagoland area that strives to deliver clinical excellence, accelerate research innovation, train the next generation of academic specialists, and advocate on behalf of children and families affected by cancer and blood disorders. The Division is uniquely positioned to enter a phase of growth that will further define the CCBD as a nationally recognized center that excels in care delivery, scientific discovery, training, and advocacy. CCBD strives to improve the health of children with cancer and blood disorders through delivering data-driven, patient-centered clinical care, contributing to discovery focused on understanding, treating, and curing cancer and blood disorders, and training the next generation of clinicians and investigators dedicated to optimizing care delivery and promoting innovation.

Patient Care

The Division ranks #1 amongst children's hospitals in Illinois and #19 in National Children's Cancer Hospitals by the *U.S. News and World Report* for 2026. The Division has experienced sustained growth in ambulatory visit volumes across all sections and programs, many of which comprise multidisciplinary, destination programs. The Division has had a successful Foundation for the Accreditation of Cellular Therapy (FACT) re-accreditation of the SCT and apheresis programs.

The CCBD strives to deliver outstanding, comprehensive, patient-centered care across the core and specialty programs. Inpatient care is delivered through a 48-bed dedicated unit on the 17th floor of the hospital, where patients are cared for by the Resident Oncology Team, the Resident Hematology Team, the APP Chemotherapy/Oncology Team, and the APP SCT Team. In the ambulatory setting, clinics occur five days per week at the main hospital as well as on select days at the satellite outreach sites. During the FY24-25 time period, providers in the CCBD cared for 476 patients with a new diagnosis of cancer. The CCBD and its four sections are home to almost 20 specialty programs, each led by a designated medical director. Clinical programs reflect the commitment to a multidisciplinary strategy for providing comprehensive care to patients and their families. Staffing models for these programs span the nursing, psychosocial, and care coordination spectrum to ensure a holistic, patient-centered model.



Education

Education remains a core mission of the CCBBD and is reflected in the educational activities implemented at all learner and trainee levels. The Division offers an outstanding ACGME-accredited 3-year fellowship program that includes three pediatric hematology/oncology fellowships per year. One of the most competitive training programs in the country, the fellowship program at Lurie Children's has successfully matched all fellowship spots every year since 2007. The CCBBD also offers 1-year advanced fellowships in neuro-oncology and stem cell transplantation/cellular therapies. Our graduating fellows go on to accept competitive faculty positions at both non-academic health systems and major academic institutions.

Research

The CCBBD has a diverse federally funded, industry-sponsored and investigator-initiated research portfolio as well as actively participate in consortium-led studies in COG, the Pediatric Neuro-oncology Consortium (PNOC), the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), the Pediatric Transplant and Cellular Therapy Consortium (PTCTC), the North American Pediatric Aplastic Anemia Consortium (NAPAAC) among others. Faculty lead major research efforts and participate in discovery and research across the basic science, translational research and clinical investigation spectrum. Over the past year alone, CCBBD faculty have had 106 unique peer-reviewed publications associated with their research activities.

Lurie Children's Hospital and the CCBBD has been an active, funded member of the NCI-sponsored Children's Oncology Group since 2000. The pediatric hematology/oncology program at Central DuPage Hospital (located in Winfield, IL), which is part of Northwestern Medicine and Lurie Children's Hospital, was recently approved to be a COG-affiliate under Lurie Children's CCBBD.

Besides participating in COG and the COG PEP-CTN, Lurie Children's CCBBD also actively engages in clinical trials through investigator-initiated efforts, industry partnerships, national collaborations as well as participation in other consortia such as the Therapeutic Advances in Childhood Leukemia (TACL), the Pediatric ITP Consortium (ICON), and the North American Consortium for Histiocytosis.

A total of 268 IRB-approved studies were open in the CCBBD from 2020 through 2025, with 149 studies currently active across the Sections of Hematology, Oncology, Neuro-Oncology & Stem Cell Transplant. During this time, awarded funds from all sources totaled over \$35 million, with approximately \$11 million in NIH funding.

SECTIONS

Hematology

The Hematology Section, including eight faculty and four APP providers, and its clinical programs are focused on delivering excellent clinical care and offering therapies that range from highly transformative—such as gene therapy for hemoglobinopathies and hemophilia—to low-cost, high-impact interventions that benefit thousands of patients, including newborn hemoglobinopathy screening and hydroxyurea therapy for sickle cell disease. Community and system partnerships further strengthen care delivery and include a Blood Donor Program, the Lydia Smith Foundation Patient Assistance Fund, collaborations with the Illinois Department of Public Health, and engagement in the SCDAl Sickle Cell Camp, BDAI Hemophilia Summer Camp, and Thalassemia Patient and Family Day events, all which support patient education, access to resources, and psychosocial well-being.



The Hematology Research Portfolio includes 25 active studies and seven upcoming studies, representing a balanced mix of NIH-sponsored, industry-sponsored, and investigator-initiated clinical research across a range of classical hematology. The program is organized around disease-focused pillars led by section faculty, including comprehensive programs in Sickle Cell Disease, Thalassemia, Bleeding and Thrombotic Disorders, each delivering care through an integrated clinical, research, and community-engaged model focused on quality, innovation, and continuity across the lifespan. In addition, two new programs in Bone Marrow Failure and Immune Hematology, developed in partnership with the Immunology team, will provide state-of-the-art care for children with complex hematologic conditions.

The program maintains a strong outreach presence through Lurie Children's clinics in Schaumburg, Lake Forest, and New Lenox and collectively serves more than 1,500 new outpatient patients annually and approximately twice that number of return visits at both the downtown and satellite locations. The inpatient and consultative hematology team include a Safe Anticoagulation Service that provides consultation for medically complex patients with, or at risk for, thrombotic disease, managing approximately 150 new blood clots annually and ensuring safe discharge planning and post-discharge follow-up of over 350 children. The Hemostasis and Thrombosis Team is also piloting Epic Healthy Planet tools to enhance care coordination, monitor quality and cost, and engage patients through a centralized data warehouse that provides a comprehensive, 360-degree view of the patient—an essential foundation for population health management

Oncology

The Oncology Section currently comprises 12 pediatric oncologists and eight advanced practice providers who collaborate with a dedicated team of pediatric surgeons, radiation oncologists, pathologists as well as ancillary service providers. The section has established programs focused on hematologic malignancies, solid tumors, cancer predisposition, fertility preservation, adolescent young adult cancer care and cancer survivorship. The section engages in clinical trials through investigator-initiated efforts and national collaborations as well as participates in consortia such as the Children's Oncology Group (COG), the COG Pediatric Early Phase-Clinical Trial Network (PEP-CTN), Therapeutic Advances in Childhood Leukemia (TACL), and North American Consortium for Histiocytosis. The section also leads programs in basic/translational and patient outcomes research.

Neuro-Oncology

The neuro-oncology section and Pediatric Brain Tumor Program includes specialists from the following divisions: pathology, radiology, endocrinology, neuropsychology, neurology, onco-dermatology, genetics and ophthalmology. Radiation oncology collaboration is through Northwestern Medicine with proton facility located in the western suburbs and photon facility on the downtown campus. Neuro-oncology specific outpatient services are provided by five neuro-oncology faculty, two APNs, and three RNs during four half-day sessions and one full day session. The Tuesday and Wednesday sessions are multi-disciplinary with clinic space allocated to neurosurgery, endocrinology, onco-dermatology, and ophthalmology. The Monday and Friday sessions are primarily staffed by APNs. As the largest pediatric brain tumor program in the regional area and the only local program with membership to early phase clinical trial consortiums, the PBT program also offers a weekly Brain Tumor Board review of internal cases, external referrals, and proton referral cases to Northwestern Medicine.



A key component of the PBT program is clinical research. The clinical trial portfolio includes Pediatric Neuro-oncology Consortium (PNOC), Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT), Neurofibromatosis (NF) Consortium, industry-sponsored trials, and investigator-initiated trials. The PBT program also belonged to the now closing Pediatric Brain Tumor Consortium (PBTC). From a clinical research space, the PBT program were the initial founding members of the Children's Brain Tumor Network and the Gift from a Child program.

Stem Cell Transplant and Cellular Therapies

The Stem Cell Transplant and Cellular Therapies (SCT-CT) Program was established in 1992 for the care of all children with cancer and blood disorders that need transplant or cellular therapy-based cures. Our mission is to provide high-quality, personalized, and innovative care that lead to excellent outcomes. The program has been FACT certified continuously since 1998 and is a center of excellence for SCD, thalassemia and Primary immune deficiency. With >1,500 transplants performed to date, the SCT team provides consultation and planning for all transplants, cellular therapy in the inpatient setting including allogenic and autologous stem cell transplant, CAR-T therapies, autologous cell-based gene therapies and donor derived cellular therapies such as cytotoxic T cells, mesenchymal stem cells, etc. The therapeutic apheresis team performs procedures such as RBC exchange, stem cell harvest, and ECP. Our outpatient services are provided through three full-day clinics in the Lurie Children's Hospital outpatient center as well as daily infusion support in the ambulatory infusion center. Our outcomes exceed current CIBMTR standards with our 100-day survival of > 95% and 1- and 2-year overall survivals of >85% and >90% in allogeneic and autologous transplants, respectively.

Beyond working with the CCBP, the SCT-CT program also consults with immunology, rheumatology, solid organ transplants for therapeutic interventions and provides expertise to the hospital's wider gene therapy program. The SCT-CT program participates in research initiatives (Investigator-initiated, federal and industry sponsored clinical trials) and is actively involved in national and international networks to support and optimize advocacy, clinical care, and research in the field of pediatric stem cell and cellular therapies.

CROSS-DISCIPLINARY COLLABORATIONS

Adolescent Young Adult Program

The Northwestern Adolescent and Young Adult (AYA) Program was launched in 2009 as a collaborative initiative to establish comprehensive, developmentally appropriate cancer care for patients aged 15 to 39 years old. Since its inception, the program has brought together a multidisciplinary team of clinicians, researchers, and advocates dedicated to addressing the unique medical, psychosocial, and developmental needs of adolescents and young adults with cancer. Historically, the program primarily served AYAs treated at downtown Chicago medical centers, delivering standardized care aligned with National Comprehensive Cancer Network (NCCN) Guidelines for AYA Oncology. However, nearly 49% of AYAs within the broader Northwestern Medicine Cancer Network (NMCN) receive care outside these downtown sites. In response, the AYA Program successfully integrated services across all 14 NMCN satellite locations this year, with a strategic focus on provider and patient education and coordinated outreach. Since implementation into satellites, the AYA team has engaged nearly 2,000 AYA patients across the network. This systemwide expansion represents a critical step toward equitable access to high-quality, leading-edge AYA cancer care throughout the Chicago metropolitan area.

Apheresis Program

What has become the Therapeutic Apheresis Program started in 1998 with the first autologous peripheral blood stem cell collections in young children with high-risk neuroblastoma. The program has become nationally recognized for its support of integral apheresis procedures in children and young adults cared for within the CCBD, including automated red blood cell exchange, peripheral blood stem cell and immune effector cell collections, and extracorporeal photopheresis. Lurie Children's is also the only pediatric center that provides lipid apheresis for patients with recurrent FSGS after kidney transplant. The program's services are available for patients Monday through Friday, with 24-hour/7-day coverage for patients with sickle cell disease who need emergency automated red blood cell exchange. Procedures are largely performed as outpatients in the Ambulatory Infusion Center.

The TAP has become known for its innovative work in performing albumin primes for low-weight healthy sibling PBSC donors to avoid transfusion exposure, and low-weight ECP procedures prior to the release of the CELLEX system. In addition, the program played a major part in the early gene therapy trials for patients with beta thalassemia and sickle cell disease starting in 2014. Since 2020, the team has performed over 600 ECP procedures and have 216 product collection days. In 2025, 100% of patients undergoing stimulated collections completed target collections in one day (excluding gene therapy patients).

Cancer Predisposition Program

The Cancer Predisposition Program based in the hematology/oncology Division was established in 2015 and originally focused on offering genetic counseling services and genetic testing in the cancer survivor population. Clinics were established to expand comprehensive genetic counseling services to all pediatric patients and families at risk of hereditary cancer syndromes. Referrals include patients with a variety of indications including personal cancer history, abnormal somatic testing results suggestive of germline cancer predisposition, personal non-cancer genetic conditions associated with cancer risk, and family cancer history and hereditary cancer predisposition syndrome. Consultations are primarily offered in the outpatient setting (in-person and telemedicine), but program staff also provide inpatient genetic counseling for hereditary cancer syndromes.

Currently, the program offers services by three physicians: 1) a general oncologist, 2) a neuro-oncologist with expertise in neurofibromatosis and laboratory-based molecular research, and 3) another oncologist with expertise in myeloid malignancies associated with bone marrow failure. The program is also supported by three genetic counselors. Additional staff include a part-time nurse who assists in coordination of care and a part-time social worker. Recently, a genetic counseling assistant was hired to assist the genetic counselors in coordination of care.

The volume of referrals has greatly expanded over the past several years due to expanded genetic testing for both oncologic and non-oncologic conditions, increasing acceptance by oncology faculty of the role of cancer predisposition, and greater community awareness of the program.

CAR T-Cell Therapy Program

Lurie Children's CCBD offers cutting-edge immunotherapy called chimeric antigen receptor (CAR) T-cell therapy.



Lurie Children's was an early adopter of this breakthrough treatment that provides a lifesaving option if chemotherapy fails. We have developed considerable expertise with CAR T-cell therapy, using a multidisciplinary approach to care for our patients. We also are actively involved with multiple consortia that work on advancing CAR T-cell therapy applications in pediatrics.

Fertility and Hormone Preservation and Restoration Program

The multi-disciplinary team brings together oncology experts, pediatric surgeons and fertility specialists to collaborate on patient care. The program participates in research to advance the field of fertility and hormone preservation and restoration to provide future options for patients. Providers in the program provide risk assessment, education, and counseling. The program is one of three pediatric hospitals in the country that provides ovarian tissue cryopreservation services in-house and collaborates with other institutions to cover all pediatric and AYA preservation options.

Hematological Malignancies

The hematological malignancies program is a clinical and research program that consists of six attending physicians, four APPs providing three FTEs, four RNs providing three FTEs, one nurse care coordinator, 1.5 social workers, one child life specialist, and four clinical research personnel who collectively care for patients with leukemia, lymphoma, and histiocytic disorders. Approximately 120 patients with newly diagnosed or relapsed disease were seen in the program in the past year. The team provides comprehensive care for a breadth of complex patients, each of whom has a primary care team (MD, APP, RN). APPs and RNs provide frontline support for clinical care and patient education. With recognized subspecialty expertise, program faculty are represented in COG disease/administrative committees, domains, and on clinical trial study committees. The program enrolls patients on COG clinical trials and serves as a PEP-CTN core site and through various consortia, including TACL, NACHO, and St. Jude. Faculty serve as institutional representatives for NCCN Guidelines for Pediatric B-ALL, Aggressive Mature B-Cell Lymphoma, and AML, and serve on guidelines panels for ASH and the College of American Pathologists. Faculty also participate in and lead multi-institutional collaborations to collect real-world experience from the program's complex and diverse patient population. In October 2025, the Advanced Leukemia Clinical and Research Program with a (\$4M) philanthropic gift from the Cal's Angels Foundation was launched to support second opinion consultations, clinical trial referrals, and translational science. The initiative highlights the program's goals to enhance regional and national reputation, increase patient referrals and engage consortia and industry sponsors for clinical trials.


Solid Tumor

The solid tumor program was established in 2009 and has grown significantly since its inception. The program focuses on multi-disciplinary care for children with solid tumors in both the inpatient and outpatient settings. The program brings together core members from Pediatric Oncology, Pediatric Surgery, Hepatobiliary Surgery, Otolaryngology, Orthopedic Surgery, Interventional Radiology, and Radiation Oncology. Faculty in the program also closely collaborate with experts from radiology, pathology, Oncology pharmacy, and clinical research. Three primary Advanced Practice Nurses, three nurses, and a program coordinator round out the team. In 2025, the program evaluated approximately 90 patients with potential new solid tumors either at up-front diagnosis or in the relapse setting.

Beyond Lurie Children's Hospital, the team participates in multiple Children's Oncology Group committees (Bone Tumor, Germ Cell Tumor, Neuroblastoma, Renal Tumor, and Soft Tissue Sarcoma) as well as other national and international consortia that focus on the treatment of pediatric solid tumors. The program actively enrolls patients on COG clinical trials, including early phase trials, as well as other investigator-initiated protocols.

Survivorship

The STAR Program was established in 2005 to deliver comprehensive, longitudinal care to survivors of pediatric cancer and hematopoietic stem cell transplantation. It is a multidisciplinary program that integrates pediatric oncologists and advanced practice nurses with specialists in cardiology, endocrinology, stem cell transplantation, and immunology, alongside coordinated care with additional subspecialties, including nephrology and neurology. The STAR Program provides evidence-based survivorship care in accordance with the Children's Oncology Group (COG) Survivorship Guidelines. In parallel, the program addresses the psychosocial and neurocognitive sequelae of pediatric cancer treatment through close collaboration with a dedicated social worker, the Lurie Cancer Center Adolescent and Young Adult (AYA) Program, and the neuropsychology team. To further reduce barriers to care, the STAR Program has recently expanded its age range to include young adults up to 39 years, ensuring continuity of survivorship care across critical developmental and healthcare transition periods. The STAR Program also supports a robust research enterprise, with ongoing projects focused on interventions to improve neurocognitive outcomes, investigations into accelerated aging among neuroblastoma survivors, and assessments of smoking and vaping behaviors in pediatric cancer survivors, as well as being a Childhood Cancer Survivorship Study site. The STAR Program delivers care at satellite Lurie locations, including Schaumburg, and prioritizes patient-centered access through family-friendly scheduling, offering afternoon clinics at both the main hospital and satellite sites.



ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO

[Ann & Robert H. Lurie Children's Hospital of Chicago](#) is one of the premier children's hospitals in the country and the only freestanding hospital in Illinois exclusively for children. Lurie Children's medical staff includes more than 1,800 physicians and allied health professionals who offer expertise in 70 pediatric specialty areas. With an inpatient capacity of 360 beds, more than 230,000 children from around the world receive the highest quality medical care each year at Lurie Children's. Services include neonatal and pediatric intensive care units, a cardiac intensive care unit, several medical and surgical acute care units, ambulatory surgery, the emergency department, three floors of outpatient clinic facilities, a full-service pediatric radiology department, and pediatric therapy specialists. Lurie Children's has 14 outpatient centers and five primary care locations throughout Chicago and its suburbs. Lurie Children's is on the medical campus of Northwestern University in Chicago and is connected via an enclosed pedestrian bridges to Northwestern Memorial Hospital and Northwestern Medicine Prentice Women's Hospital. Lurie Children's is the pediatric training and teaching hospital of Northwestern University Feinberg School of Medicine and one of a few children's hospitals in the country to have its own research center devoted to pediatric diseases, Stanley Manne Children's Research Institute.

DEPARTMENT OF PEDIATRICS AT NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE

Led by Tara O. Henderson, MD, MPH, [The Department of Pediatrics at Northwestern University Feinberg School of Medicine](#) represents the primary academic affiliate partner of Ann & Robert H. Lurie Children's Hospital of Chicago and is a premier academic institution dedicated to pediatric clinical care, research, education and childhood advocacy. The department comprises more than 900 faculty across 23 specialized divisions to provide comprehensive services and care covers a full spectrum, from primary care to advanced, specialized treatments for complex, rare, and acute conditions. The department also represents the training ground for nationally recognized accredited programs in resident education in general pediatrics and fellowship education in 14 subspecialties. Faculty conduct high-level basic, translational, and clinical research to improve child health through the Stanley Manne Children's Research Institute.

STANLEY MANNE CHILDREN'S RESEARCH INSTITUTE


Faculty and investigators at the [Stanley Manne Children's Research Institute](#) at Ann & Robert H. Lurie Children's Hospital of Chicago investigate a range of children's health and diseases across the translational science spectrum. Manne Research Institute studies are led by over 750 researchers and staff and are organized into four scientific pillars: Basic and Preclinical Science; Clinical and Community Trials; Community, Population Health, and Outcomes; and Quantitative Science. Researchers include physicians, scientists, postdocs, coordinators, statisticians, data analysts, trainees, and others who share their expertise. Manne Research Institute pediatricians and scientists routinely collaborate with the research institute's academic partner, Northwestern University, and other medical centers and academic institutions across the globe, as well as with community partners such as schools and governments.

Manne Research Institute receives more than \$80.6 million in external funding annually for research, two-thirds of that from the National Institutes of Health and other federal agencies. It is one of the nation's premier institutes for pediatric research, investing more dollars and resources in pediatric research than any other area hospital. In addition to clinical and population health

research facilities, Manne Research Institute has approximately 125,000 square feet of state-of-the-art laboratory space. In 2019, Manne Research Institute wet-lab research moved into the Louis A. Simpson & Kimberly K. Querrey Biomedical Research Building located on the Northwestern University Chicago campus. This building includes wet-bench laboratories, animal facilities, and conference, educational, office, and collaborative space. It is adjacent to Northwestern University research resources and is located just one city block from Lurie Children's. Stanley Manne Children's Research Institute is dedicated to improving equitable access to healthcare for every person. Manne Research Institute researchers collaborate with experts at Patrick M. Magoon Institute for Healthy Communities who facilitate programs devoted to building trust and partnerships to identify health-related problems and the social and structural influences that contribute to healthcare disparities across all populations.

ROBERT H. LURIE COMPREHENSIVE CANCER CENTER OF NORTHWESTERN UNIVERSITY

Lurie Children's and Robert H. Lurie Comprehensive Cancer Center have a deeply integrated pediatric oncology partnership in collaboration through Northwestern University. This structure allows pediatric and adult cancer specialists to collaborate in research, clinical trials, and translational research. The collaboration provides pediatric cancer patients with access to clinical trials, research conducted through the Stanley Manne Children's Research Institute and Northwestern University, advanced therapies and multidisciplinary care and supportive services. This creates a continuum that supports pediatric cancer care, research, early-phase clinical trials, survivorship programs, and transition of adolescent patients into adult oncology programs when appropriate.



THE COMMUNITY

CHICAGO, ILLINOIS


The City of Chicago covers an area of 600 square kilometers and sits 176 meters (578 feet) above sea level on the southwestern shore of Lake Michigan. The lake is about 300 miles long and averages 75 miles across, making it the fifth-largest body of fresh water in the world. The city is traversed by the Chicago and Calumet rivers. Chicago's extensive parklands, including 30 square kilometers of city parks attract an estimated 86 million visitors annually.

As a multicultural city that thrives on the harmony and diversity of its neighborhoods, Chicago today embodies the values of America's heartland – integrity, hard work and community – and reflects the ideals in the social fabric of its 77 distinct neighborhoods.

Chicago is recognized across the United States as a very passionate sports town with five major sporting franchises – The Bulls, Cubs, White Sox, Blackhawks, and Bears. Each team knows what it is like to win and bring home the hardware to their city.

Chicago is a leader in reforming public schools, enhancing public safety and security initiatives, providing affordable housing in attractive and economically sound communities, ensuring accessibility for all and fostering social, economic, and environmental sustainability.





PROCEDURE FOR CANDIDACY

Please direct all nominations and applications to Kerry Quealy, Jeff Schroetlin, and Fayth Hoecker preferably via e-mail to fhoecker@wittkieffer.com.


Formal application materials must also be submitted via the Northwestern University jobs portal, located at <https://facultyrecruiting.northwestern.edu/apply/MjU1NA==> prior to formal review by the search committee.

The anticipated base salary for this position is \$390,000–\$480,000, commensurate with qualifications, experience, and demonstrated leadership accomplishments. This represents the institution's good-faith estimate of compensation at the time of posting. Final compensation will be based on a variety of factors, and the organization is committed to offering a competitive compensation package and may exercise flexibility to attract an exceptional candidate. Additional incentive compensation and comprehensive benefits are provided.

Lurie Children's values and celebrates the diverse identities that build and enrich our hospital and Chicago community. We seek employees who share a variety of perspectives and life experiences because diverse identities and perspectives strengthen the fabric of our medical center. Lurie Children's cultivates an open, affirming, and inclusive work environment for all staff.

The material presented in this leadership profile should be relied on for informational purposes only. This material has been copied, compiled, or quoted in part from Lurie Children's documents and personal interviews and is believed to be reliable. While every effort has been made to ensure the accuracy of this information, the original source documents and factual situations govern.

All images and logos used in this leadership profile were attained from Lurie Children's and/or are owned by Witt/Kieffer Inc. via Getty Images.



WittKieffer is the premier executive search and leadership advisory firm developing impactful leadership teams for organizations that improve quality of life. We work exclusively with organizations in healthcare, science and education—the Quality of Life Ecosystem. Leveraging our unwavering focus on this complex ecosystem, we amplify clients’ ability to succeed through a deep understanding of the factors that influence leadership needs, capabilities and culture. Through our executive search, interim leadership and leadership advisory solutions, we strengthen organizations that make the world better. WittKieffer is proud to be 100 percent employee-owned.

Visit [WittKieffer.com](https://www.wittkieffer.com) to learn more.

